🎉 Excited to be part of this work published in Journal of Medicinal Chemistry @ACSPublications
Here we designed Pt(IV) prodrugs of ALK inhibitors (crizotinib or ceritinib) to tackle ALK-rearranged non–small cell lung cancer (NSCLC).
https://t.co/T3CCrM5dgK
Check out our recent report on Multiaction Pt(IV) Prodrugs Releasing Cisplatin and Dasatinib Are Potent Anticancer and Anti-Invasive Agents Displaying Synergism between the Two Drugs | Journal of Medicinal Chemistry https://t.co/BVPLOkM7ei
Our review article with @CLCCLeonBerard on the strategies to deliver metal complexes to the nucleus of cancer cells is now out in Advanced Materials @AdvSciNews. BIG congratulations to @MarHuynh and @RVinck.
@ChimieParisTech@psl_univ
https://t.co/kyv90XsaLe
Happy to see it online! Sincere thanks to all the co-authors!
Cytotoxic Imidazolyl-Mesalazine Ester-Based Ru(II) Complexes Reduce Expression of Stemness Genes and Induce Differentiation of Oral Squamous Cell Carcinoma| Journal of Medicinal Chemistry https://t.co/IfCysQMmlg
Multitargeting Prodrugs Inhibit Tumor Growth and Induce Cell Death: Prodrug releases oxaliplatin, doxorubicin, and gemcitabine in their active form upon cellular reduction https://t.co/M7SbV3FHrG